Table 2. Comparison of the demographic and clinical features of the COV-FA and other groups.
| Characteristic | Total (n = 110) |
COV-FA (n = 30) |
Other (n = 80) |
p-value |
|---|---|---|---|---|
| Age, year, median (IQR) | 63 (54–70) | 63 (52–71) | 63 (54–68) | 0.631 |
| Gender, n (%) | ||||
| – Male | 40 (36.4) | 6 (20.0) | 34 (42.5) | 0.049 |
| – Female | 70 (63.6) | 24 (80.0) | 46 (57.5) | |
| Cancer, n (%) | ||||
| – Breast | 28 (25.5) | 13 (43.3) | 15 (18.8) | NA |
| – Colorectal | 22 (20.0) | 7 (23.3) | 15 (18.8) | |
| – Ovarian | 12 (10.9) | 3 (10.0) | 9 (11.2) | |
| – Lung | 11 (10.0) | 2 (6.7) | 9 (11.2) | |
| – Pancreas | 9 (8.2) | 2 (6.7) | 7 (8.8) | |
| – Gastric | 8 (7.3) | 0 (0) | 8 (10.0) | |
| – Other | 20 (18.1) | 3 (10.0) | 17 (21.2) | |
| Stage, n (%) | ||||
| – II | 10 (9.1) | 3 (10.0) | 7 (8.8) | 0.323 |
| – III | 23 (20.9) | 9 (30.0) | 14 (17.5) | |
| – IV | 77 (70.0) | 18 (60.0) | 59 (73.8) | |
| Regimen, n (%) | ||||
| – Platin doublet | 25 (22.7) | 7 (23.3) | 18 (22.4) | NA |
| – Paclitaxel | 11 (10.0) | 4 (13.3) | 7 (8.8) | |
| – FOLFOX-6 | 9 (8.2) | 2 (6.7) | 7 (8.8) | |
| – Gemcitabine | 7 (6.4) | 0 (0) | 7 (8.8) | |
| – Capecitabine + oxaliplatin | 6 (5.5) | 1 (3.3) | 5 (6.2) | |
| – 5-FU based + Anti-EGFR | 6 (5.5) | 2 (6.7) | 4 (5.0) | |
| – 5-FU based + Anti-VEGF | 6 (5.5) | 2 (6.7) | 4 (5.0) | |
| – FOLFIRI | 4 (3.6) | 0 (0) | 4 (5.0) | |
| – Other | 36 (32.6) | 12 (40.0) | 24 (30.0) | |
| CT, n (%) | ||||
| – Neoadjuvant | 5 (4.5) | 1 (3.3) | 4 (5.0) | 0.583 |
| – Definitive | 2 (1.8) | 1 (3.3) | 1 (1.2) | |
| – Adjuvant | 25 (22.7) | 9 (30.0) | 16 (20.0) | |
| – Palliative | 78 (70.9) | 19 (63.4) | 59 (73.8) | |
COV-FA: COVID-19 fear and anxiety; CT: Chemotherapy; IQR: Interquartile range; NA: Not applicable; FOLFIRI: Folinic acid, fluorouracil and irinotecan.